Dr. Christos Papageorgiou
Claim this profileMU Health - University Hospital/Ellis Fischel Cancer Center
Studies Breast Cancer
Studies Cancer
9 reported clinical trials
24 drugs studied
Area of expertise
1Breast Cancer
ER positive
HER2 positive
HER2 negative
2Cancer
HER2 positive
ER positive
PR positive
Affiliated Hospitals
Clinical Trials Christos Papageorgiou is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Marker-Directed Monitoring
for Breast Cancer
This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.
Recruiting1 award N/A
More about Christos Papageorgiou
Clinical Trial Related1 year of experience running clinical trials · Led 9 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Christos Papageorgiou has experience with
- Questionnaire Administration
- Biospecimen Collection
- Paclitaxel
- No Radiation
- Radiation
- Imlunestrant
Breakdown of trials Christos Papageorgiou has run
Breast Cancer
Cancer
Progesterone Receptor Positive
Tumor Markers
No change needed.
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christos Papageorgiou specialize in?
Christos Papageorgiou focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved ER positive patients, or patients who are HER2 positive.
Is Christos Papageorgiou currently recruiting for clinical trials?
Yes, Christos Papageorgiou is currently recruiting for 8 clinical trials in Columbia Missouri. If you're interested in participating, you should apply.
Are there any treatments that Christos Papageorgiou has studied deeply?
Yes, Christos Papageorgiou has studied treatments such as Questionnaire Administration, Biospecimen Collection, Paclitaxel.
What is the best way to schedule an appointment with Christos Papageorgiou?
Apply for one of the trials that Christos Papageorgiou is conducting.
What is the office address of Christos Papageorgiou?
The office of Christos Papageorgiou is located at: MU Health - University Hospital/Ellis Fischel Cancer Center, Columbia, Missouri 65212 United States. This is the address for their practice at the MU Health - University Hospital/Ellis Fischel Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.